Evidence map›Paper›PMID 42095472›Full record

ArticleBiotechnology journal2026

A New Conditional Transcription Factor for Use in Toxoplasma Gondii.

Mohammad Farouq Sharifpour, Shadi Khadiv, Alessandro D Uboldi, Amalie A Jayawickrama, Sarah Manning, Jonathan Whittall, Cynthia D K Bottema, John T Ellis, Daniel K Howe, Danny W Wilson and 3 more

Abstract read
In one paragraph

Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mohammad Farouq SharifpourAustralian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia.ORCID https://orcid.org/0000-0002-7950-955X
Shadi KhadivSchool of Veterinary Sciences, College of Science and Engineering, James Cook University, Townsville, Queensland, Australia.
Alessandro D UboldiThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Amalie A JayawickramaThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Sarah ManningSouth Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Jonathan WhittallSchool of Biological Sciences, Adelaide University, Adelaide, South Australia, Australia.
Cynthia D K BottemaSchool of Animal and Veterinary Sciences, Roseworthy Campus, Adelaide University, Roseworthy, South Australia, Australia.ORCID https://orcid.org/0000-0001-6245-0099
John T EllisSchool of Life Sciences, University of Technology - Sydney, Sydney, New South Wales, Australia.
Daniel K HoweDepartment of Veterinary Science, Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky, USA.
Danny W WilsonResearch Centre For Infectious Diseases, School of Biological Sciences, Adelaide University, Adelaide, South Australia, Australia.
Farhid HemmatzadehSchool of Animal and Veterinary Sciences, Roseworthy Campus, Adelaide University, Roseworthy, South Australia, Australia.
Christopher J TonkinThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Milton M McAllisterSchool of Animal and Veterinary Sciences, Roseworthy Campus, Adelaide University, Roseworthy, South Australia, Australia.

Funding

Adelaide University
6 · The paper itself

Abstract

Toxoplasma gondii is an intracellular eukaryotic parasite in the phylum Apicomplexa. Reversible, conditional control of gene transcription was achieved previously in this organism using a tet-off system that was controlled by tetracycline. Although revolutionary for the field at the time, that system in Toxoplasma yielded modest signal-to-noise ratios (SNR) and proved to be leaky in the "off" state (i.e., it suffered from high background expression). Here we report the development of a new reversible and robust Conditional Transcription Factor (CTF) that is controlled by rapamycin. Although we originally intended to design a dimerizable drug-on transcription control system, the CTF unexpectedly functions in a drug-off fashion. In stably-transfected tachyzoites, CTF regulates a fluorescent reporter gene in Toxoplasma to achieve almost no background expression in the presence of rapamycin (i.e. near-zero leakiness), while in the absence of rapamycin 84% of tachyzoites express EYFP in comparison with 87% of constitutively-expressed positive controls, with 59% mean fluorescence intensity relative to positive controls. Conditional regulation of the median fluorescence intensity of the reporter gene reached an impressive SNR averaging 1489, approximating an "on/off" switch. The modular design of the CTF is expected to facilitate application to varied genes, incremental modifications, and adaptation for use in other apicomplexan organisms.

Indexed as

SirolimusToxoplasmaTranscription FactorsGene Expression RegulationGenes, ReporterGenetic VectorsLuminescent ProteinsSignal-To-Noise RatioTranscription, GeneticLuminescent ProteinsSirolimusTranscription Factorsapicomplexaartificial transcription factorconditional gene expressionFKBPgene regulationrapamycinsignal‐to‐noise ratio

Identifiers

PMID42095472
PMCPMC13150947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.